Source comparison
CJC-1295 vs GHRP-2 Acetate: Side-by-Side Comparison
The following table directly compares CJC-1295 vs GHRP-2 Acetate across the parameters that determine research protocol design. Mechanism, half-life, dosing frequency, peak effect timing, and ideal application. Receptor Target GHRH receptors (pituitary somatot
This comparison does not assign a generated winner or score.
- The following table directly compares CJC-1295 vs GHRP-2 Acetate across the parameters that determine research protocol design. Mechanism, half-life, dosing frequency, peak effect timing, and ideal application.
- Receptor Target
- GHRH receptors (pituitary somatotrophs)
- GHS-R1a ghrelin receptors (pituitary and hypothalamus)
- Different pathways. Synergistic when combined
- Half-Life
- 6–8 days (albumin-bound)
- 20–30 minutes (rapid clearance)
- CJC-1295 sustains; GHRP-2 spikes
- Dosing Frequency
- Once weekly or biweekly
- 2–3 times daily
- CJC-1295 suits chronic studies; GHRP-2 suits acute protocols
- Peak GH Elevation
- 1.5–3× baseline, sustained 7+ days
- 5–10× baseline, peaks at 30–45 min, returns to baseline in 2–4 hours
- GHRP-2 produces higher peaks but no sustained elevation
- IGF-1 Increase
- 1.5–2× baseline, sustained across dosing interval
- Transient increase, returns to baseline within 24 hours
- CJC-1295 sustains IGF-1; GHRP-2 does not
- Preserves Natural Pulsatility
- Yes. Amplifies endogenous pulses
- No. Creates pharmacological pulses independent of circadian rhythm
- CJC-1295 maintains physiological patterns
- Secondary Hormone Effects
- Minimal prolactin/cortisol effect
- Modest prolactin and cortisol increase
- GHRP-2 activates additional pathways
- Ideal Research Application
- Chronic anabolism, body composition, tissue repair studies requiring weeks of treatment
- Acute signaling studies, dose-response experiments, controlled pulse studies
- Use CJC-1295 for chronic outcomes, GHRP-2 for acute mechanistic studies
- Synergy with Other Peptides
- Synergistic with GHRP-2 or other ghrelin mimetics
- Synergistic with CJC-1295 or other GHRH analogs
- Combination protocols outperform single-peptide designs